JP5504259B2 - 第ｉｘａ因子阻害剤としての複素環式化合物 - Google Patents

第ｉｘａ因子阻害剤としての複素環式化合物 Download PDF

Info

Publication number
JP5504259B2
JP5504259B2 JP2011510610A JP2011510610A JP5504259B2 JP 5504259 B2 JP5504259 B2 JP 5504259B2 JP 2011510610 A JP2011510610 A JP 2011510610A JP 2011510610 A JP2011510610 A JP 2011510610A JP 5504259 B2 JP5504259 B2 JP 5504259B2
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
aryl
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011510610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520967A (ja
JP2011520967A5 (enExample
Inventor
マーティン シー． クラスビー，
ウィリアム ジェイ． グリーンリー，
サミュエル チャッカラマニール，
ヤン シア，
シャオバン ガオ，
マリアッパン ブイ． シェリアー，
キース エー． イーガン，
ヘンリー バッカロ，
ティン−ヤウ チャン，
ブライアン マッキトリック，
リ ユアン ワン，
ハイヤン プ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5504259(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2011520967A publication Critical patent/JP2011520967A/ja
Publication of JP2011520967A5 publication Critical patent/JP2011520967A5/ja
Application granted granted Critical
Publication of JP5504259B2 publication Critical patent/JP5504259B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2011510610A 2008-05-19 2009-05-18 第ｉｘａ因子阻害剤としての複素環式化合物 Expired - Fee Related JP5504259B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5431008P 2008-05-19 2008-05-19
US61/054,310 2008-05-19
PCT/US2009/044291 WO2009143039A2 (en) 2008-05-19 2009-05-18 Heterocyclic compounds as factor ixa inhibitors

Publications (3)

Publication Number Publication Date
JP2011520967A JP2011520967A (ja) 2011-07-21
JP2011520967A5 JP2011520967A5 (enExample) 2012-06-07
JP5504259B2 true JP5504259B2 (ja) 2014-05-28

Family

ID=41066042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011510610A Expired - Fee Related JP5504259B2 (ja) 2008-05-19 2009-05-18 第ｉｘａ因子阻害剤としての複素環式化合物

Country Status (11)

Country Link
US (1) US8148363B2 (enExample)
EP (2) EP2300435A2 (enExample)
JP (1) JP5504259B2 (enExample)
CN (1) CN102099340A (enExample)
AR (1) AR071823A1 (enExample)
CA (1) CA2724430A1 (enExample)
CL (1) CL2009001214A1 (enExample)
MX (1) MX2010012635A (enExample)
PE (1) PE20091972A1 (enExample)
TW (1) TW201008930A (enExample)
WO (1) WO2009143039A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149755A1 (en) * 2009-06-26 2010-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
US8242284B1 (en) * 2009-09-21 2012-08-14 The United States Of America As Represented By The United States Department Of Energy Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making
CN110269856A (zh) 2010-03-30 2019-09-24 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
AR083431A1 (es) * 2010-06-28 2013-02-27 Bayer Cropscience Ag Compuestos heterociclicos como pesticidas
CN103313976B (zh) 2010-06-30 2016-11-23 铁木医药有限公司 sGC刺激物
EP2637659B1 (en) 2010-11-09 2016-05-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators
AU2012249421B9 (en) 2011-04-28 2015-10-22 Novartis Ag 17alpha-hydroxylase/C17,20-lyase inhibitors
US9161924B2 (en) 2011-07-08 2015-10-20 Merck Sharp & Dohme Corp. Factor IXa inhibitors
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
CN102660253B (zh) * 2012-03-07 2014-05-21 泰山医学院 一种吡唑啉衍生物类Ni2+荧光探针及其应用
US9695198B2 (en) 2012-12-19 2017-07-04 Merck Sharp & Dohme Corp. Factor IXa inhibitors
WO2014099695A1 (en) * 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. Factor ixa inhibitors
EP2934538B1 (en) * 2012-12-19 2021-03-31 Merck Sharp & Dohme Corp. Factor ixa inhibitors
KR20150130405A (ko) 2013-03-15 2015-11-23 베르선 코포레이션 트롬빈의 억제제로서의 할로게노피라졸
RU2678830C2 (ru) * 2013-03-15 2019-02-04 Версеон Корпорейшн Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
EP3193600A4 (en) * 2014-09-10 2018-05-23 Epizyme, Inc. Smyd inhibitors
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
WO2016044645A1 (en) * 2014-09-17 2016-03-24 Elmaleh David R Anticoagulant derivatives for cardiovascular imaging
WO2016087615A1 (en) 2014-12-04 2016-06-09 Procomcure Biotech Gmbh Novel imidazole-based heterocyclic compounds
SI3226858T1 (sl) 2014-12-04 2021-07-30 Procomcure Biotech Gmbh Protimikrobna sredstva na osnovi imidazola
US10351558B2 (en) 2015-02-16 2019-07-16 Merck Sharp & Dohme Corp. Factor IXa inhibitors
HK1246164A1 (zh) 2015-02-27 2018-09-07 Verseon Corporation 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
SI3440076T1 (sl) 2016-04-07 2022-09-30 Glaxosmithkline Intellectual Property Development Limited Heterociklični amidi uporabni kot proteinski modulatorji
BR112018070602A2 (pt) * 2016-04-07 2019-02-05 Glaxosmithkline Ip Dev Ltd composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
WO2018093716A1 (en) * 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
WO2018175670A1 (en) 2017-03-22 2018-09-27 The Research Foundation For The State University Of New York Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same
US11498905B2 (en) * 2018-04-17 2022-11-15 The Regents Of The University Of Michigan Inhibitors of platelet function and methods for use of the same
CN112457308B (zh) * 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用
WO2022081573A1 (en) * 2020-10-12 2022-04-21 University Of Tennessee Research Foundation Transient receptor potential canonical 3 inhibitors and methods of use thereof
WO2022078407A1 (en) * 2020-10-13 2022-04-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN114149371B (zh) * 2021-11-26 2023-08-22 首都医科大学 四取代吡唑类化合物及其应用
CN114478511B (zh) * 2022-02-24 2023-06-20 中国药科大学 苯并恶唑类化合物及其制备方法、药物组合物和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
CN1149196C (zh) 1998-07-06 2004-05-12 布里斯托尔-迈尔斯斯奎布公司 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
JP4642318B2 (ja) 2000-06-15 2011-03-02 シェーリング コーポレイション トロンビンレセプターアンタゴニスト
US7235567B2 (en) 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
ATE525378T1 (de) 2001-10-18 2011-10-15 Schering Corp Himbacinanaloga als thrombinrezeptorantagonisten
EP1441725A1 (en) * 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
SI2065384T1 (sl) 2002-04-16 2011-05-31 Schering Corp Tricikliäśni trombin receptor antagonist
EP1667983A4 (en) * 2003-09-23 2010-07-21 Merck Sharp & Dohme PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
CA2572745A1 (en) * 2004-07-07 2006-02-16 Teresa Beeson Pyrazole amide derivatives, compositions containing such compounds and methods of use
AU2005269792B9 (en) * 2004-07-22 2008-11-27 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
JP5063351B2 (ja) * 2004-09-17 2012-10-31 エグゼリクシス， インコーポレイテッド ピラゾールキナーゼモジュレーターおよび使用方法
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
US7968683B1 (en) * 2008-05-07 2011-06-28 Schering Corporation Factor IXa crystals, related complexes and methods
JP2011520897A (ja) * 2008-05-16 2011-07-21 シェーリング コーポレイション グルカゴン受容体アンタゴニスト、組成物およびそれらの使用方法

Also Published As

Publication number Publication date
EP2805939A1 (en) 2014-11-26
AR071823A1 (es) 2010-07-14
PE20091972A1 (es) 2010-01-15
US8148363B2 (en) 2012-04-03
CN102099340A (zh) 2011-06-15
TW201008930A (en) 2010-03-01
US20110065682A1 (en) 2011-03-17
EP2805939B1 (en) 2018-06-27
WO2009143039A2 (en) 2009-11-26
WO2009143039A3 (en) 2010-07-08
CA2724430A1 (en) 2009-11-26
CL2009001214A1 (es) 2010-12-31
JP2011520967A (ja) 2011-07-21
EP2300435A2 (en) 2011-03-30
MX2010012635A (es) 2010-12-06

Similar Documents

Publication Publication Date Title
JP5504259B2 (ja) 第ｉｘａ因子阻害剤としての複素環式化合物
US8609676B2 (en) 4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors
JP7579789B2 (ja) 免疫調節剤、組成物およびその使用方法
ES2329881T3 (es) Compuestos que contienen lactama y derivados de los mismos como inhibidores del factor xa.
JP4795336B2 (ja) 血栓症病態の治療に有用なｐ２ｙ１レセプターのウレアアンタゴニスト
US20040132732A1 (en) Quinazolinones and derivatives thereof as factor Xa inhibitors
US20040209863A1 (en) Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US20050119266A1 (en) Pyrrolidine and piperidine derivatives as factor Xa inhibitors
CN109790169A (zh) 具有作为usp30抑制剂活性的氰基吡咯烷衍生物
MX2007012712A (es) Fenil-acetamidas adecuadas como inhibidores de cinasa de proteina.
AU2013276519B2 (en) 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
RS57659B1 (sr) Makrociklusi sa heterocikličnim p2' grupama kao inhibitori faktora xia
EP3131896B1 (en) Factor ixa inhibitors
KR20110075010A (ko) 키나제 억제제로서 유용한 이미다조피리다진카르보니트릴
CA2648250A1 (en) Deazapurines useful as inhibitors of janus kinases
CN112521369A (zh) 用于抑制fasn的化合物及组合物
CA2681516A1 (en) Compounds useful as inhibitors of janus kinases
US12371432B2 (en) Haloallylamine compounds and application thereof
US20030144287A1 (en) Novel N-[4- (1H-imidazol-1-yl) -2-fluorophenyl ] -3- (trifluoromethyl) -1H-pyrazole-5-carboxamides as factor Xa inhibitors
CN115894376B (zh) 一种芳香族酰胺类化合物、药物组合物及其用途
KR20250038764A (ko) Tead 억제제 및 사용 방법
HK40087839A (zh) 哌嗪环状脲
HK40053245A (en) Haloallylamine compounds and application thereof
KR20070022867A (ko) 세린 프로테아제 억제제로서 유용한 6원 헤테로사이클

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140127

TRDD Decision of grant or rejection written
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140214

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140317

R150 Certificate of patent or registration of utility model

Ref document number: 5504259

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

LAPS Cancellation because of no payment of annual fees